Let’s face it, venture capital financing is in the doldrums, notoriously few new drugs are making it to market, and healthcare spending is under increasing scrutiny. But innovation is messy—and often the best innovations spring from tough times. Today’s difficult climate is breeding creative and flexible new models for launching and sustaining companies in biotech, diagnostics, medical devices, and other areas of life sciences.
This conference and networking event will bring top innovators, entrepreneurs, and investors together for a series of case studies and panel discussions on these new strategies—including alternative forms of financing, novel types of collaboration, non-traditional business models, and more. So join us on September 23 and learn what your colleagues and competitors are doing to build the next generation of great life sciences companies.
Robert Langer — Institute Professor, MIT
Terry McGuire — Co-founder and Managing General Partner, Polaris Venture Partners
Speakers and panelists include:
Nils Bergenhem — Chief Scientific Officer, Escoublac
Myer Berlow — CEO, Nano-Terra; Director, Diagnostics-For-All
Leo Liu — Founder and CEO, Cambria Pharmaceuticals
Nick Naclerio — CEO and Chairman, Quanterix
Amir Nashat — General Partner, Polaris Venture Partners
Alex Rives–Associate, ARCH Venture Partners
Carmichael Roberts — General Partner, North Bridge Venture Partners; co-founder Surface Logix, Nano-Terra
Clifford J. Robinson — Director, Business Incubation, Boston University
David Schubert — Chief Business Officer, Accelerator Corporation
David Steinberg — CEO, Enlight Biosciences; Senior Principal, PureTech Ventures
Chuck Wilson — Vice President, Global Head of Strategic Alliances, Novartis
Tod Woolf — CEO, RXi Pharmaceuticals
Breakfast and lunch will be served.